Cliff Asness's VRDN Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 20,208 shares of Viridian Therapeutics, Inc. (VRDN) worth $395,269, representing 0.00% of the portfolio. First purchased in 2022-Q4, this short-term holding has been held for 5 quarters.
Based on 13F filings, Cliff Asness has maintained this position in VRDN for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 20,208 shares. Largest reduction occurred in Q3 2023, reducing 12,005 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Viridian Therapeutics (VRDN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Viridian Therapeutics (VRDN) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +20,208 | New Buy | 20,208 | $19.56 |
| Q3 2023 | -12,005 | Sold Out | 0 | $0.00 |
| Q2 2023 | +1,634 | Add 15.76% | 12,005 | $23.79 |
| Q1 2023 | +2,968 | Add 40.09% | 10,371 | $25.44 |
| Q4 2022 | +7,403 | New Buy | 7,403 | $29.21 |
Cliff Asness's Viridian Therapeutics Investment FAQs
Cliff Asness first purchased Viridian Therapeutics, Inc. (VRDN) in Q4 2022, acquiring 7,403 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Viridian Therapeutics, Inc. (VRDN) for 5 quarters since Q4 2022.
Cliff Asness's largest addition to Viridian Therapeutics, Inc. (VRDN) was in Q1 2026, adding 20,208 shares worth $395,269.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 20,208 shares of Viridian Therapeutics, Inc. (VRDN), valued at approximately $395,269.
As of the Q1 2026 filing, Viridian Therapeutics, Inc. (VRDN) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Viridian Therapeutics, Inc. (VRDN) was 20,208 shares, as reported at the end of Q1 2026.